Item 8.01 Other Events.
On October 19, 2021, Sage Therapeutics, Inc. issued a press release titled "Sage
Therapeutics and Biogen Announce Plans to Submit a New Drug Application (NDA)
for Zuranolone to the U.S. Food & Drug Administration in the Second Half of 2022
with Rolling Submission Expected to Start in Early 2022." A copy of the press
release is filed as Exhibit 99.1 hereto and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press release issued by Sage Therapeutics, Inc. on October 19, 2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses